State Tracker Updated June 15, 2026

Alaska: what the PBM reimbursement law requires

Alaska regulates PBMs through MAC transparency and appeals, an anti-self-dealing parity rule, and a spread-pricing ban — but it sets no NADAC or acquisition-cost reimbursement floor.

Status	Partially enacted
Law	HB 226 (2024) — AS 21.36.520; MAC appeal at AS 21.27.950
Effective date	January 1, 2025 (MAC appeal in force since July 1, 2019)
Reimbursement basis	No reimbursement floor. PBMs must keep MAC lists current and disclose NADAC and WAC, may not reimburse a pharmacy less than they pay an affiliate for the same service (anti-self-dealing parity), and may not use spread pricing. NADAC appears only as a disclosure field, not a payment floor.
Professional dispensing fee	Not specified in statute
Appeal route	Multi-source generic appeal resolved within 10 calendar days; if upheld, reimbursement is adjusted to the pharmacy's acquisition cost; adverse decisions are appealable to a hearing within 30 days

Alaska does not set a reimbursement floor. Its 2024 PBM law (HB 226, effective January 1, 2025) requires PBMs to keep maximum-allowable-cost (MAC) lists current and to disclose the national average drug acquisition cost and wholesale acquisition cost, but those figures are disclosure fields, not a minimum the PBM must pay.

The law does include an anti-self-dealing parity rule — a PBM may not reimburse an independent pharmacy less than it pays its own affiliate for the same service — and bans spread pricing. A pharmacy can appeal a multi-source generic reimbursement; if the appeal succeeds, the PBM adjusts payment to the pharmacy’s acquisition cost for those claims.

Sources

Enrolled HB 226 — Alaska State Legislature (BASIS) Primary source
AS 21.27.950 — Multi-source generic drug appeal (codified) Primary source

Back to the tracker